Therapeutics & Diagnostics

CCI has a robust pipeline of TxDx technologies, due in part to Cleveland Clinic’s world- class Lerner Research Institute. CCI works closely with all investigators to translate their findings into a marketable product or compound.
 
CCMCL 1: A New Model of Aggressive Mantle Cell Lymphoma

CCMCL 1: A New Model of Aggressive Mantle Cell Lymphoma

This is a HIA partner technology

Eric Hsi, MD

Mantle cell lymphoma (MCL) is incurable using current standard therapeutic regimens. Additionally, there are relatively few cell lines and mouse models to support drug discovery and development efforts.


Genetic Mechanism Augments DHT Synthesis in CRPC

Genetic Mechanism Augments DHT Synthesis in CRPC

This is a HIA partner technology

Nima Sharifi, MD

The technology is a diagnostic tool that assesses an actionable biomarker for treatment selection in the prostate cancer care continuum.


Humanized Anti-CD6 mAb for Treating of Autoimmune Diseases

Humanized Anti-CD6 mAb for Treating of Autoimmune Diseases

This is a HIA partner technology

Feng Lin, PhD

Dr. Lin's research suggests that targeting CD6 gene is a promising effective treatment for Multiple Sclerosis.


In-vitro Platform for Drug Identification, Selection and Prioritization Toward Preclinical and Clinical Development

In-vitro Platform for Drug Identification, Selection and Prioritization Toward Preclinical and Clinical Development

This is a HIA partner technology

Frederic Reu, MD

Despite progress, multiple myeloma remains largely incurable, recruiting relapses from genetically heterogeneous multiple myeloma subclones.


Localized Therapy of PSMA Expressing Tumors Utilizing a Radiolabeled PSMA Targeting Tracer

Localized Therapy of PSMA Expressing Tumors Utilizing a Radiolabeled PSMA Targeting Tracer

This is a HIA partner technology

Steve Shih Lin Huang, MD, PhD

Researchers at Cleveland Clinic have developed peptide tracers that target prostate specific membrane antigen (PSMA).


Photosorb Polyhydroxy Fullerene Sunscreen

Photosorb Polyhydroxy Fullerene Sunscreen

This is a HIA partner technology

Sanjay Anand; Vijay Krishna, PhD; Edward Maytin, MD PhD; Stephen Grobmyer, MD

Photosorb is a sunscreen developed with a unique active ingredient, polyhydroxy fullerene molecules.  


Protein Disulfide Isomerase Inhibitors with Anticancer Activity in Multiple Myeloma

Protein Disulfide Isomerase Inhibitors with Anticancer Activity in Multiple Myeloma

This is a HIA partner technology

Frederic Reu, MD; Eric Hsi

Despite progress, multiple myeloma remains largely incurable, recruiting relapses from genetically heterogeneous multiple myeloma subclones.


Recombinant β2-glycoprotein I in the Diagnosis of the Antiphospholipid Syndrome

Recombinant β2-glycoprotein I in the Diagnosis of the Antiphospholipid Syndrome

This is a HIA partner technology

Keith McCrae, MD

Antiphospholipid syndrome is the most common cause of acquired thrombophilia and a major cause of vascular morbidity and mortality.


Sensitizing Neoplastic Cells to Radiation

Sensitizing Neoplastic Cells to Radiation

This is a HIA partner technology

Mohamed Abazeed, MD, PhD

Resistance to chemotherapy and radiation is a significant obstacle toward more effective cancer therapeutics.


Small Molecule for Hematological Malignancies

Small Molecule for Hematological Malignancies

This is a HIA partner technology

Neeta Gupta, PhD

Various oncogenic pathways are deregulated in Diffused Large B-Cell Lymphoma (DLBCL), including B cell antigen receptor (BCR) signaling pathway.


Previous 1 2 Next 
 

Get In Touch With Us